GELESIS HOLDINGS, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | -99.99% |
|
-99.95% | -99.93% |
| 19/04 | Bidding Procedure Approved for Gelesis Holdings, Inc. | CI |
| 09/04 | Motion for Asset Sale Filed by Gelesis Holdings, Inc. | CI |
Presenter SpeechEliana Merle (Analysts)Okay. Good morning, everyone. Thank you for joining us ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Gelesis Holdings, Inc. is a commercial stage biotherapeutics company built for consumer engagement. The Company focuses on advancing superabsorbent hydrogel therapeutics for chronic gastrointestinal (GI) diseases including excess weight, type two diabetes, Nonalcoholic Fatty Liver Disease (NAFLD)/ Nonalcoholic Steatohepatitis (NASH), functional constipation (FC), and inflammatory bowel disease. Its product, Plenity, is an orally administered capsule. Plenity is available by prescription via a telehealth consultation with a physician trained in weight management support, with free, unlimited follow-up visits as needed. Consumers can visit myplenity.com for online consultations. Its other pipeline candidate includes GS200 for weight loss in prediabetes and type two diabetes. It is also developing GS300 for the treatment of NAFLD and NASH, and GS500 for the treatment of Functional Constipation (FC).
Sector
Pharmaceuticals
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -99.93% | 73 | |
| +34.20% | 693B | |
| +29.39% | 584B | |
| -2.95% | 372B | |
| +20.61% | 332B | |
| +6.55% | 294B | |
| +14.11% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.91% | 168B |
- Stock Market
- Equities
- GLSH.Q Stock
- News Gelesis Holdings, Inc.
- Transcript : Gelesis Holdings, Inc. Presents at UBS Global Healthcare Conference, May-25-2022 08
